NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News $11.55 -0.09 (-0.77%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$11.30▼$11.7950-Day Range$11.50▼$18.0852-Week Range$6.15▼$22.11Volume1.33 million shsAverage Volume2.25 million shsMarket Capitalization$1.23 billionP/E Ratio13.13Dividend YieldN/APrice Target$21.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalyst Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside86.1% Upside$21.50 Price TargetShort InterestHealthy9.55% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.18Based on 18 Articles This WeekInsider TradingSelling Shares$3.97 M Sold Last QuarterProj. Earnings Growth16.81%From $1.13 to $1.32 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.84 out of 5 starsMedical Sector35th out of 983 stocksPharmaceutical Preparations Industry15th out of 486 stocks 3.4 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.50, Catalyst Pharmaceuticals has a forecasted upside of 86.1% from its current price of $11.55.Amount of Analyst CoverageCatalyst Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.55% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently decreased by 15.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 1.8 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 43 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -6% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,974,706.00 in company stock.Percentage Held by Insiders14.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.66% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 16.81% in the coming year, from $1.13 to $1.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 13.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 13.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 105.35.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Pharmaceuticals (NASDAQ:CPRX) StockCatalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.Read More Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Stock News HeadlinesJune 1, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023June 1, 2023 | msn.comCatalyst maintains FY23 revenue outlookJune 4, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...June 1, 2023 | finance.yahoo.comWall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest?June 1, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023May 31, 2023 | americanbankingnews.comFY2024 Earnings Forecast for Catalyst Pharmaceuticals, Inc. Issued By Zacks Research (NASDAQ:CPRX)May 31, 2023 | americanbankingnews.comFY2025 EPS Estimates for Catalyst Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:CPRX)May 30, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Appoints Tamar Thompson to its Board of DirectorsJune 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 27, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Lowered by Zacks ResearchMay 22, 2023 | finance.yahoo.comDown 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?May 19, 2023 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) CEO Sells $345,977.73 in StockMay 19, 2023 | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Lowered to Hold at StockNews.comMay 18, 2023 | americanbankingnews.comCatalyst Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CPRX)May 16, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Issued By HC WainwrightMay 13, 2023 | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 17.3%May 13, 2023 | finance.yahoo.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2023 Earnings Call TranscriptMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Catalyst Pharmaceuticals (CPRX) Buy RecommendationMay 12, 2023 | finance.yahoo.comShould You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views?May 12, 2023 | markets.businessinsider.comCatalyst Pharma (CPRX) Receives a Buy from H.C. WainwrightMay 11, 2023 | msn.comCatalyst Pharmaceuticals: Q1 Earnings InsightsMay 11, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-YearMay 11, 2023 | finance.yahoo.comCatalyst's (CPRX) Q1 Earnings Lag, Sales Boost RevenuesMay 11, 2023 | seekingalpha.comCatalyst Pharmaceuticals (CPRX) Q1 2023 Earnings Call TranscriptMay 11, 2023 | finance.yahoo.comCatalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) high institutional ownership speaks for itself as stock continues to impress, up 5.5% over last weekMay 10, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms marketMay 10, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-YearSee More Headlines CPRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Company Calendar Last Earnings3/15/2023Today6/04/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees76Year Founded2002Price Target and Rating Average Stock Price Forecast$21.50 High Stock Price Forecast$25.00 Low Stock Price Forecast$15.50 Forecasted Upside/Downside+86.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio13.13 Forward P/E Ratio10.22 P/E GrowthN/ANet Income$83.08 million Net Margins38.76% Pretax Margin48.57% Return on Equity34.72% Return on Assets28.75% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.33 Sales & Book Value Annual Sales$214.20 million Price / Sales5.72 Cash Flow$0.81 per share Price / Cash Flow14.26 Book Value$3.15 per share Price / Book3.67Miscellaneous Outstanding Shares106,080,000Free Float91,120,000Market Cap$1.23 billion OptionableOptionable Beta1.10 Social Links Key ExecutivesPatrick J. McEnanyChairman, President & Chief Executive OfficerSteven R. MillerChief Operating & Scientific OfficerAlicia GrandeCFO, Treasurer, Principal Accounting Officer & VPGary IngenitoChief Medical & Regulatory OfficerStanley IyaduraiSenior VP-Medical Affairs & Drug DiscoveryKey CompetitorsTravere TherapeuticsNASDAQ:TVTXLigand PharmaceuticalsNASDAQ:LGNDBiomea FusionNASDAQ:BMEAIDEAYA BiosciencesNASDAQ:IDYACrinetics PharmaceuticalsNASDAQ:CRNXView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,243 shares on 5/26/2023Ownership: 0.013%Capital Impact Advisors LLCBought 1,497 shares on 5/23/2023Ownership: 0.043%Seaport Global Advisors LLCSold 5,257 shares on 5/23/2023Ownership: 0.015%Ameriprise Financial Inc.Sold 181,502 shares on 5/22/2023Ownership: 0.429%Putnam Investments LLCSold 1,038 shares on 5/22/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions CPRX Stock - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price forecast for 2023? 4 brokers have issued twelve-month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price forecasts range from $15.50 to $25.00. On average, they expect the company's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2023? Catalyst Pharmaceuticals' stock was trading at $18.60 at the beginning of 2023. Since then, CPRX stock has decreased by 37.9% and is now trading at $11.55. View the best growth stocks for 2023 here. Are investors shorting Catalyst Pharmaceuticals? Catalyst Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 9,490,000 shares, a decline of 15.2% from the April 30th total of 11,190,000 shares. Based on an average trading volume of 1,920,000 shares, the days-to-cover ratio is currently 4.9 days. Approximately 9.6% of the shares of the company are short sold. View Catalyst Pharmaceuticals' Short Interest. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings data on Wednesday, March, 15th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.01. The biopharmaceutical company earned $60.76 million during the quarter, compared to the consensus estimate of $60.64 million. Catalyst Pharmaceuticals had a net margin of 38.76% and a trailing twelve-month return on equity of 34.72%. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Aztlan Global Stock Selection DM SMID ETF (AZTD), Innovator IBD 50 ETF (FFTY), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), ALPS Medical Breakthroughs ETF (SBIO) and Invesco S&P SmallCap Momentum ETF (XSMO). What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $375.00 million-$385.00 million, compared to the consensus revenue estimate of $381.54 million. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (14.54%), State Street Corp (7.11%), Dimensional Fund Advisors LP (2.25%), Geode Capital Management LLC (1.75%), Two Sigma Advisers LP (1.49%) and Jupiter Asset Management Ltd. (1.35%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $11.55. How much money does Catalyst Pharmaceuticals make? Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.23 billion and generates $256.48 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $0.88 on an earnings per share basis. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933. This page (NASDAQ:CPRX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.